Search Results - "Amadori, S."

The impact of Mild Behavioral Impairment on the individual’s level of psychological, social, and occupational functioning by Elefante, C., Brancati, G.E., Gemmellaro, T., Ricciardulli, S., Romeo, F., Torrigiani, S., Pistolesi, G., Amadori, S., Lattanzi, L., Perugi, G.

“…Introduction Mild behavioral impairment (MBI) is a neurobehavioral syndrome characterized by later-life emergent neuropsychiatric symptoms, which represent an…”
Get full text

PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy by Cicconi, L, Divona, M, Ciardi, C, Ottone, T, Ferrantini, A, Lavorgna, S, Alfonso, V, Paoloni, F, Piciocchi, A, Avvisati, G, Ferrara, F, Di Bona, E, Albano, F, Breccia, M, Cerqui, E, Sborgia, M, Kropp, M G, Santoro, A, Levis, A, Sica, S, Amadori, S, Voso, M T, Mandelli, F, Lo-Coco, F

“…The APL0406 study showed that arsenic trioxide (ATO) and all -trans retinoic acid (ATRA) are not inferior to standard ATRA and chemotherapy (CHT) in newly…”
Get full text

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab by STASI, R, STIPA, E, DEL POETA, G, AMADORI, S, NEWLAND, A. C, PROVAN, D

“…Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be quite effective in the treatment of immune disorders resulting from autoantibodies…”
Get full text

Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia by Noguera, N I, Song, M S, Divona, M, Catalano, G, Calvo, K L, García, F, Ottone, T, Florenzano, F, Faraoni, I, Battistini, L, Colombo, E, Amadori, S, Pandolfi, P P, Lo-Coco, F

“…PTEN (phosphatase and tensin homolog deleted in chromosome 10) is a bona fide dual lipid and protein phosphatase with cytoplasmic (Cy) and nuclear…”
Get full text

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia by Buccisano, F, Maurillo, L, Piciocchi, A, Del Principe, M I, Picardi, A, Cerretti, R, Cudillo, L, De Angelis, G, Sarlo, C, Cefalo, M, Ditto, C, Di Veroli, A, Mariotti, B, Nasso, D, De Bellis, E, Del Poeta, G, Voso, M T, Sconocchia, G, Lo Coco, F, Arcese, W, Amadori, S, Venditti, A

Get full text

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults by Provan, Drew, Butler, Tom, Evangelista, Maria Laura, Amadori, Sergio, Newland, Adrian C, Stasi, Roberto

“…From Department of Haematology, Bart’s & The London, Queen Mary’s School of Medicine and Dentistry, Whitechapel, London, UK (DP, TB, ACN); Department of…”
Get full text

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes by Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E., Amadori, S.

“…Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously…”
Get full text

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia by NOGUERA, N. I, AMMATUNA, E, ZANGRILLI, D, LAVORGNA, S, DIVONA, M, BUCCISANO, F, AMADORI, S, MECUCCI, C, FALINI, B, LO-COCO, F

“…Mutations in the Nucleophosmin (NPM1) gene have been recently described to occur in about one-third of acute myeloid leukemias (AML) and represent the most…”
Get full text

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients by Buccisano, F., Maurillo, L., Piciocchi, A., Del Principe, M. I., Sarlo, C., Cefalo, M., Ditto, C., Di Veroli, A., De Santis, G., Irno Consalvo, M., Fraboni, D., Panetta, P., Palomba, P., Attrotto, C., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Amadori, S., Venditti, A.

“…In the present analysis, we evaluated whether in elderly acute myeloid leukemia (AML) patients (>60 years), minimal residual disease (MRD) assessed by flow…”
Get full text

Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia by Del Poeta, G, Bruno, A, Del Principe, M I, Venditti, A, Maurillo, L, Buccisano, F, Stasi, R, Neri, B, Luciano, F, Siniscalchi, A, de Fabritiis, P, Amadori, S

“…Apoptosis plays a key role in the control of rapidly renewing tissues, such as the hematopoietic system and leukemia cells invariably have abnormalities in one…”
Get more information

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study by Amadori, Sergio, Suciu, Stefan, Jehn, Ulrich, Stasi, Roberto, Thomas, Xavier, Marie, Jean-Pierre, Muus, Petra, Lefrère, Francois, Berneman, Zwi, Fillet, George, Denzlinger, Claudio, Willemze, Roel, Leoni, Pietro, Leone, Giuseppe, Casini, Marco, Ricciuti, Francesco, Vignetti, Marco, Beeldens, Filip, Mandelli, Franco, De Witte, Theo

“…The role of glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) in the induction treatment of older adults with acute myeloid leukemia…”
Get full text

The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia by BUCCISANO, F, MAURILLO, L, OTTAVIANI, L, FRABONI, D, TAMBURINI, A, LO-COCO, F, AMADORI, S, VENDITTI, A, GATTEI, V, DEL POETA, G, DEL PRINCIPE, M. I, COX, M. C, PANETTA, P, CONSALVO, M. Irno, MAZZONE, C, NERI, B

“…We assessed by multiparametric flow cytometry the levels of minimal residual disease (MRD) in 100 adult patients with acute myelogenous leukemia (AML)…”
Get full text

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial by DE WITTE, Theo, HAGEMEIJER, Anne, AMADORI, Sergio, MUUS, Petra, JANSEN, Joop H, HELLSTRÖM-LINDBERG, Eva, KOVACSOVICS, Tibor, WIJERMANS, Pierre, OSSENKOPPELE, Gert, GRATWOHL, Alois, MARIE, Jean-Pierre, WILLEMZE, Roel, SUCIU, Stefan, BELHABRI, Amin, DELFORGE, Michel, KOBBE, Guido, SELLESLAG, Dominik, SCHOUTEN, Harry C, FERRANT, Augustin, BIERSACK, Harald

“…Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic…”
Get full text

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT by Hengeveld, M, Suciu, S, Chelgoum, Y, Marie, J-P, Muus, P, Lefrère, F, Mandelli, F, Pane, F, Amadori, S, Fioritoni, G, Labar, B, Baron, F, Cermak, J, Bourhis, J-H, Storti, G, Fazi, P, Hagemeijer, A, Vignetti, M, Willemze, R, de Witte, T

“…The faster hematopoietic recovery after autologous peripheral blood SCT (APBSCT) in patients with AML may be offset by an increased relapse risk as compared…”
Get full text

S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE‐AGENT CONTINUATION IN PATIENTS AGED 18‐75 YEARS WITH NEWLY DIAGNOSED FLT3‐ITD+ AML by Erba, H., Montesinos, P., Vrhovac, R., Patkowska, E., Kim, H.‐J., Zak, P., Wang, P.‐N., Mitov, T., Hanyok, J., Liu, L., Benzohra, A., Lesegretain, A., Cortes, J., Perl, A., Sekeres, M., Dombret, H., Amadori, S., Wang, J., Levis, M., Schlenk, R.

Get full text

S125: 10‐DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS‐SG by Lübbert, M., Wijermans, P., Kicinski, M., Chantepie, S., Velden, W., Noppeney, R., Griskevicius, L., Neubauer, A., Crysandt, M., Vrhovac, R., Luppi, M., Fuhrmann, S., Audisio, E., Candoni, A., Legrand, O., Foà, R., Gaidano, G., Lammeren‐Venema, D., Posthuma, E. F., Hoogendoorn, M., Giraut, A., Stevens‐Kroef, M., Jansen, J. H., Ammatuna, E., Vilque, J.‐P., Wäsch, R., Becker, H., Blijlevens, N., Dührsen, U., Baron, F., Suciu, S., Amadori, S., Venditti, A., Huls, G.

Get full text

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial) by Willemze, R., Suciu, S., Muus, P., Halkes, C. J. M., Meloni, G., Meert, L., Karrasch, M., Rapion, J., Vignetti, M., Amadori, S., de Witte, T., Marie, J. P.

“…This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine…”
Get full text

Gemtuzumab ozogamicin (Mylotarg ) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups by AMADORI, S, SUCIU, S, PRUIJT, J, NOBILE, F, CASSIBBA, V, MARIE, J.-P, BEELDENS, F, BAILA, L, VIGNETTI, M, DE WITTE, T, STASI, R, WILLEMZE, R, MANDELLI, F, SELLESLAG, D, DENZLINGER, C, MUUS, P, STAUDER, R, BERNEMAN, Z

“…The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were…”
Get full text

A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy by Postorino, M., Pupo, L., Provenzano, I., Del Principe, M. I., Buccisano, F., Franceschini, L., Rizzo, M., Nasso, D., Meconi, F., Onnis, I., Vaccarini, S., Zizzari, A., Anemona, L., Mauramati, S., Bruno, E., Cantonetti, M., Amadori, S.

Get full text

Low temperature anelasticity in Ti6Al4V alloy and Ti6Al4V-SiCf composite by AMADORI, S, BONETTI, E, PASQUINI, L, DEODATI, P, DONNINI, R, MONTANARI, R, TESTANI, C

Get full text